Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Liana Adam"'
Autor:
Wassim Kassouf, Teruo Inamoto, Peter C. Black, Mark B. Fisher, David Gallagher, David J. McConkey, Colin P.N. Dinney, Gordon A. Brown, Liana Adam, Tony Luongo, Menashe Bar-Eli
Publikováno v:
Journal of Urology. 180:1146-1153
The epidermal growth factor receptor inhibitor gefitinib (Iressa) is currently being studied in patients with bladder cancer and it has significant anti-angiogenic activity. We investigated the relationship between the modulation of vascular endothel
Autor:
Mark F. Munsell, Ameeta Arora, Marissa Shrader, David J. McConkey, Liana Adam, Teruo Inamoto, Colin P.N. Dinney, Xifeng Wu, Arlene O. Siefker-Radtke, Gordon A. Brown, Dan Theodorescu, Peter C. Black, Menashe Bar-Eli
Publikováno v:
Clinical Cancer Research. 14:1478-1486
Purpose: Epidermal growth factor receptor (EGFR) is an attractive target for the treatment of urothelial carcinoma, but a clinical response can be expected in only a small proportion of patients. The aim of this study was to define molecular markers
Autor:
Jolanta Bondaruk, Tomasz Tuziak, David J. McConkey, Menashe Bar-Eli, Bogdan Czerniak, Liana Adam, Colin P.N. Dinney, Wassim Kassouf, Sangkyou Lee, Keith A. Baggerly, Gordon A. Brown, Caimiao Wei, Peter C. Black
Publikováno v:
Journal of Urology. 179:353-358
Expression of various members of the ErbB family (epidermal growth factor receptor/ErbB-1, ErbB-2, ErbB-3 and ErbB-4) is associated with disease stage and survival in patients with urothelial carcinoma. We examined the correlation of ErbB family rece
Publikováno v:
Journal of Urology. 176:787-792
We determined the sequence specific efficacy of gefitinib and docetaxel treatment for bladder cancer. This combination was selected because it is currently under study in a phase II clinical trial.In vitro antiproliferative effects of gefitinib, doce
Publikováno v:
The Urologic clinics of North America. 32(2)
The tremendous amount of data accumulated through genomics, proteomics, and meta-bolomic technologies has not led to a definitive understanding of the mechanisms underlying cancer. The challenge remains as to how to integrate all of the relevant know